116 related articles for article (PubMed ID: 8675231)
1. alpha-Interferon treatment of patients with chronic fatigue syndrome.
See DM; Tilles JG
Immunol Invest; 1996; 25(1-2):153-64. PubMed ID: 8675231
[TBL] [Abstract][Full Text] [Related]
2. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
[TBL] [Abstract][Full Text] [Related]
3. Immunological response in chronic hepatitis C virus infection during interferon alpha therapy.
Panasiuk A; Prokopowicz D; Zak J
Hepatogastroenterology; 2004; 51(58):1088-92. PubMed ID: 15239252
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
Stelma F; de Niet A; Tempelmans Plat-Sinnige MJ; Jansen L; Takkenberg RB; Reesink HW; Kootstra NA; van Leeuwen EM
J Infect Dis; 2015 Oct; 212(7):1042-51. PubMed ID: 25791117
[TBL] [Abstract][Full Text] [Related]
6. Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C.
Appasamy R; Bryant J; Hassanein T; Van Thiel DH; Whiteside TL
Clin Immunol Immunopathol; 1994 Dec; 73(3):350-7. PubMed ID: 7955564
[TBL] [Abstract][Full Text] [Related]
7. Immunologic abnormalities in chronic fatigue syndrome.
Klimas NG; Salvato FR; Morgan R; Fletcher MA
J Clin Microbiol; 1990 Jun; 28(6):1403-10. PubMed ID: 2166084
[TBL] [Abstract][Full Text] [Related]
8. Decrease in CD3-negative-CD8dim(+) and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection.
Pár G; Rukavina D; Podack ER; Horányi M; Szekeres-Barthó J; Hegedüs G; Paál M; Szereday L; Mózsik G; Pár A
J Hepatol; 2002 Oct; 37(4):514-22. PubMed ID: 12217606
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.
Millar BC; Bell JB; Powles RL
Br J Cancer; 1996 Jan; 73(2):236-40. PubMed ID: 8546912
[TBL] [Abstract][Full Text] [Related]
10. N-acetylcysteine does not affect the lymphocyte proliferation and natural killer cell activity responses to exercise.
Nielsen HB; Secher NH; Kappel M; Pedersen BK
Am J Physiol; 1998 Oct; 275(4):R1227-31. PubMed ID: 9756554
[TBL] [Abstract][Full Text] [Related]
11. Effects of HDV infection and pegylated interferon α treatment on the natural killer cell compartment in chronically infected individuals.
Lunemann S; Malone DF; Grabowski J; Port K; Béziat V; Bremer B; Malmberg KJ; Manns MP; Sandberg JK; Cornberg M; Ljunggren HG; Wedemeyer H; Björkström NK
Gut; 2015 Mar; 64(3):469-82. PubMed ID: 24721903
[TBL] [Abstract][Full Text] [Related]
12. Recombinant alpha-2b-interferon may restore natural-killer activity in patients with B-chronic lymphocytic leukemia.
Villamor N; Reverter JC; Montserrat E; Urbano-Ispízua A; Vives-Corrons JL; Rozman C
Leukemia; 1992 Jun; 6(6):547-52. PubMed ID: 1376376
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells.
Mihaylova I; DeRuyter M; Rummens JL; Bosmans E; Maes M
Neuro Endocrinol Lett; 2007 Aug; 28(4):477-83. PubMed ID: 17693977
[TBL] [Abstract][Full Text] [Related]
14. [Quality of life in patients with chronic hepatitis C after PEG-Interferon a-2a therapy].
Liu J; Lin CS; Hu SH; Liang ML; Zhao ZX; Gao ZL
Zhonghua Gan Zang Bing Za Zhi; 2011 Dec; 19(12):890-3. PubMed ID: 22525499
[TBL] [Abstract][Full Text] [Related]
15. Decreased nitric oxide-mediated natural killer cell activation in chronic fatigue syndrome.
Ogawa M; Nishiura T; Yoshimura M; Horikawa Y; Yoshida H; Okajima Y; Matsumura I; Ishikawa J; Nakao H; Tomiyama Y; Kanayama Y; Kanakura Y; Matsuzawa Y
Eur J Clin Invest; 1998 Nov; 28(11):937-43. PubMed ID: 9824439
[TBL] [Abstract][Full Text] [Related]
16. Interferon alpha 2b decreases hepatic micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells.
Yang H; Dithmar S; Grossniklaus HE
Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2056-64. PubMed ID: 15223777
[TBL] [Abstract][Full Text] [Related]
17. Adrenergic blockade ameliorates cellular immune responses to mental stress in humans.
Bachen EA; Manuck SB; Cohen S; Muldoon MF; Raible R; Herbert TB; Rabin BS
Psychosom Med; 1995; 57(4):366-72. PubMed ID: 7480566
[TBL] [Abstract][Full Text] [Related]
18. Tolerance and feasibility of perioperative treatment with interferon-alpha 2a in advanced cancers.
Houvenaeghel G; Bladou F; Blache JL; Olive D; Monges G; Jacquemier J; Chaudet H; Delpero JR; Guérinel G
Int Surg; 1997; 82(2):165-9. PubMed ID: 9331846
[TBL] [Abstract][Full Text] [Related]
19. Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion.
Bruder Costa J; Dufeu-Duchesne T; Leroy V; Bertucci I; Bouvier-Alias M; Pouget N; Brevot-Lutton O; Bourliere M; Zoulim F; Plumas J; Aspord C;
PLoS One; 2016; 11(6):e0158297. PubMed ID: 27348813
[TBL] [Abstract][Full Text] [Related]
20. Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.
Lunde S; Kristoffersen EK; Sapkota D; Risa K; Dahl O; Bruland O; Mella O; Fluge Ø
PLoS One; 2016; 11(8):e0161226. PubMed ID: 27536947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
